Opendata, web and dolomites

OXYPREM SIGNED

Precise brain oxygen monitoring for high-risk preterm infants

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXYPREM project word cloud

Explore the words cloud of the OXYPREM project. It provides you a very rough idea of what is the project "OXYPREM" about.

annually    chronic    reducing    surviving    fixed    disabilities    worth    market    prototypes    alerting    precision    university    15    global    opportunity    commercialization    head    damage    consists    capitalizing    unnecessary    die    o2    intensive    spectroscopy    cardiovascular    levels    company    grow    cagr2017    monitor    biocompatible    urgent    algorithms    life    business    globally    spin    translates    adults    therapy    zurich    oxygen    little    degree    unmet    world    swiss    babies    shown    supply    reliability    neurodevelopment    deaths    nirs    neonatal    tissue    62    designed    savings    clinical    preterm    care    5x    infrared    neonatologists    435    competitors    transforming    variation    preterms    immature    2024    ag    impairment    billion    variations    sensor    signals    initially    oximeters    opposed    compelling    medical    oximeter    saturation    lacking    quality    paralysis    created    actual    meant    ones    near    oxygenation    reusable    irreversible    oxyprem    born    off    easier    disposable    respiratory    viability    decrease    running    silicone    answer    brain    million   

Project "OXYPREM" data sheet

The following table provides information about the project.

Coordinator
OXYPREM AG 

Organization address
address: FRAUENKLINIKSTRASSE 10
city: ZURICH
postcode: 8091
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXYPREM AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Globally, 15 million preterm babies are born annually (435,000 in Europe), from which 1 million die. Even when surviving, they may face disabilities, such as neurodevelopment impairment or paralysis. Since their respiratory and cardiovascular systems are immature, they need early oxygen (O2) therapy. Tissue oximeters are medical devices needed to monitor the actual level of O2 supply in their brain, since little O2 variations can produce irreversible damage. However, current devices are adapted from tissue oximeters initially meant for adults, lacking the precision and reliability preterm babies need. World leading neonatologists have been alerting about the urgent need to develop tissue oximeters specifically designed for preterms, to decrease unnecessary deaths and chronic disabilities. OxyPrem is our answer: a brain oximeter created just for preterm babies and providing the degree of precision and reliability they need. OxyPrem consists of (1) a high-quality Near-Infrared Spectroscopy (NIRS) sensor embedded in biocompatible silicone that is fixed to the preterm's head to monitor brain O2-levels, and a (2) monitor running advanced analysis algorithms transforming the signals into tissue oxygenation saturation measurements. OxyPrem prototypes have shown unmet levels of precision in clinical studies, reducing 5x the variation observed with competitors. Furthermore, our reusable sensor (opposed to the disposable ones from competitors), translates into important savings. OxyPrem represents a compelling business opportunity, capitalizing from the global neonatal intensive care market, worth €5.6 billion and expected to grow at a CAGR2017-2024 of 5.62%. The commercialization of OxyPrem is key to the viability of our company OxyPrem AG, a Swiss spin-off from University of Zurich, born to make preterm life's easier.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXYPREM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXYPREM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More